|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
NMDA receptor antagonist
dopamine reuptake inhibitor
|
|
gptkbp:approves
|
gptkb:1966
gptkb:FDA
|
|
gptkbp:clinical_trial
|
90%
Phase IV
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to amantadine
|
|
gptkbp:dosage_form
|
gptkb:beer
gptkb:product
gptkb:tablet
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Symmetrel
|
|
gptkbp:ingredients
|
gptkb:amantadine
C10 H17 N
|
|
gptkbp:interacts_with
|
gptkb:beer
anticholinergic drugs
CNS stimulants
|
|
gptkbp:invention
|
gptkb:2011
|
|
gptkbp:is_atype_of
|
J05 A B01
|
|
gptkbp:is_used_for
|
gptkb:psychologist
treatment of influenza
|
|
gptkbp:lifespan
|
10 to 14 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Endo_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:name
|
Essential Medicines
|
|
gptkbp:previous_name
|
amantadine hydrochloride
|
|
gptkbp:side_effect
|
anxiety
dizziness
nausea
insomnia
dry mouth
|
|
gptkbp:traded_on
|
Amantadine
|
|
gptkbp:weight
|
151.25 g/mol
|
|
gptkbp:bfsParent
|
gptkb:amantadine
|
|
gptkbp:bfsLayer
|
6
|